Targeted Oncology Launches its Latest Virtual Tumor Board on Multiple Myeloma
<em>Targeted Oncology</em>™ will launch its third “Expert Perspective: Virtual Tumor Board” on Monday, September 24. Each Virtual Tumor Board is a video-editorial discussion that features key opinion leaders from a specific oncological field considering options for treating patients based on case scenarios. This episode will focus on multiple myeloma.
Targeted Oncology™, a print and digital resource that offers content and expert opinions on standard and emerging treatments in the oncology field, will launch its third “Expert Perspective: Virtual Tumor Board” on Monday, September 24. Each Virtual Tumor Board is a video-editorial discussion that features key opinion leaders from a specific oncological field considering options for treating patients based on case scenarios. This episode will focus on multiple myeloma.
“We look forward to launching the next Virtual Tumor Board on September 24,” said Michael J. Hennessy Jr., president of MJH Associates Inc., parent company ofTargeted Oncology. “Expert leaders will really get the chance to dive in to several patient’s cases and truly help make a difference in the multiple myeloma community.”
The Virtual Tumor Board will feature experts providing in-depth analysis on four patients with multiple myeloma and sharing information on their diagnoses, pathology results and treatment strategies from a collaborative medical setting based on recent data and clinical trial findings. With these cases, the multidisciplinary team discuss high-risk cytogenetics, maintenance therapy, the possibility for CAR T-cell therapy, and more for specific instances of multiple myeloma.
The key opinion leaders participating in this Virtual Tumor Board are:
- Ajai Chari, M.D., associate professor, department of medicine, hematology and medical oncology, Mount Sinai Hospital
- C. Ola Landgren, M.D., Ph.D., board-certified hematologic-oncologist, Memorial Sloan Kettering Cancer Center
- Pei Lin, M.D., professor and section chief, myeloma, The University of Texas MD, Anderson Cancer Center
- Nina Shah, M.D., associate professor, hematologist-oncologist, University of California San Francisco
About Targeted Oncology™
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More
Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma
April 22nd 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More
